Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Overview of attention for article published in Journal of Hematology & Oncology, April 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 63 Dimensions

Readers on

mendeley: 49 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 63 publications that cite this research output.

63

The most recent citing publications are shown below. View all 63 publications that cite this research output on Dimensions.

Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer

Article in Cancer Science (April 2024)

Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: A real-world clinical study

Article in iLiver (March 2024)

Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review

Article in Cancer Cell International (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.